Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.
Strasser-Weippl K, et al.
Breast Cancer Res. 2015 Apr 16;17(1):56. doi: 10.1186/s13058-015-0568-1.
Breast Cancer Res. 2015.
PMID: 25888246
Free PMC article.